• Sign in to follow this  

    Alcobra (ADHD) Phase 3 Results of Metadoxine for ADHD in Adults

       (0 reviews)

    Biotech Forecast
    Clinical and Regulatory
    Event Type: Phase 3 Results
    Timing: H2 2016
    Designation(s): None

    This event is set for a broad date range and therefore the exact timing is unknown. This adds a degree of risk.
    FDA special designations may increase the likelihood of success and decrease the time to approval.
    Learn More

    Disease and Treatment
    Disease: Neurology
    Indication: Adult ADHD
    Lead Indication?: Yes
    Treatment Name: Metadoxine Extended Release

    Likelihood of event success varies depending on disease, treatment and lead indication classification.
    Learn More

    Company Information
    Co. Name: Alcobra
    Stock Symbol: ADHD
    Shares Traded: NASDAQ

    The OTC BB and OTC Markets have less stringent reporting and financial requirements than the NASDAQ and NYSE. This may increase the level of risk for investors. Smaller size may have an influence on likelihood of success.
    Learn More

    Event Status
    Event Outcome: Ongoing
    Event Discussion: Forums
    Event Announcement(s): http://www.alcobra-pharma.com/releasedetail.cfm?ReleaseID=955293
    Partnership: No

    Partnerships help smaller biotech companies finance the long approval process. Partnership also provides validation the clinical program may be a worthy investment.
    Learn More

    Detailed Event Description from Company Announcement

    Quote

    The company is currently enrolling patients into the MEASURE study (MDX Evaluation in Adults — Study of Response and Efficacy). The MEASURE study is the company's second Phase III study of Metadoxine Extended Release (MDX) in adults with ADHD. The study includes design and operational elements to potentially mitigate a placebo response and reduce response variability. Based on trends in recent enrollment rates, the company now expects data from the study by year end 2016.

     


      Report Event
    Sign in to follow this  


    User Feedback

    There are no reviews to display.